Abiopharma

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohns disease at two years

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

ADC Therapeutics to Present at November Investor Conferences

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

Incyte annonce de nouveaux résultats issus de l’essai de phase 3b TRuE-AD4 sur Opzelura® (crème à base de ruxolitinib) chez des adultes atteints de dermatite atopique modérée

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

Immatics Appoints Amie Krause as Chief People Officer

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics